MSD is expecting to see an additional $200 million layered onto its costs this year as a result of President Trump's tariffs – even before a possible pharma-specific levy is announced. The US pharma ...
MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback